Drug hypersensitivity: pharmacogenetics and clinical syndromes.

[1]  S. Murad,et al.  Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population , 2011, International journal of dermatology.

[2]  S. Mallal,et al.  Pharmacogenetics of drug hypersensitivity. , 2010, Pharmacogenomics.

[3]  R. Hui,et al.  Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. , 2010, Pharmacogenomics.

[4]  M. Muramatsu,et al.  HLA Class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions , 2010, Epilepsia.

[5]  Yuan-Tsong Chen,et al.  Genetic predisposition of life-threatening antiepileptic-induced skin reactions , 2010, Expert opinion on drug safety.

[6]  C. Joshi,et al.  Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. , 2009, Indian journal of dermatology, venereology and leprology.

[7]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[8]  Yusuke Nakamura,et al.  HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients , 2009, Pharmacogenetics and genomics.

[9]  B. Kuehn.  FDA: Epilepsy drugs may carry skin risks for Asians. , 2008, JAMA.

[10]  Yuan-Tsong Chen,et al.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.

[11]  K. Suphapeetiporn,et al.  Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.

[12]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[13]  E. Phillips,et al.  A review of drug patch testing and implications for HIV clinicians , 2008, AIDS.

[14]  A. Romano,et al.  Association of tumor necrosis factor-α –308G>A polymorphism with IgE-mediated allergy to betalactams in an Italian population , 2008, The Pharmacogenomics Journal.

[15]  S. Mallal,et al.  High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[17]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[18]  H. Uchi,et al.  Stevens-Johnson Syndrome, Drug-Induced Hypersensitivity Syndrome and Toxic Epidermal Necrolysis Caused by Allopurinol in Patients with a Common HLA Allele: What Causes the Diversity? , 2007, Dermatology.

[19]  P. Kwan,et al.  Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.

[20]  M. Mockenhaupt,et al.  Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist? , 2007, The British journal of dermatology.

[21]  H. Yazaki,et al.  HLA-Cw8 primarily associated with hypersensitivity to nevirapine. , 2007, AIDS.

[22]  A. Romano,et al.  Gene–gene interactions of IL13 and IL4RA variants in immediate allergic reactions to betalactam antibiotics , 2006, Pharmacogenetics and genomics.

[23]  C. Carcassi,et al.  HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients , 2006, AIDS.

[24]  P. Demoly,et al.  IL‐10 promoter and IL4‐Rα gene SNPs are associated with immediate β‐lactam allergy in atopic women , 2006 .

[25]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[26]  M. Schumacher,et al.  A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.

[27]  S. Mallal,et al.  Clinical and immunogenetic correlates of abacavir hypersensitivity , 2005, AIDS.

[28]  J. Roujeau.  Clinical heterogeneity of drug hypersensitivity. , 2005, Toxicology.

[29]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Moore,et al.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.

[31]  Hailing Qiao,et al.  Specific serum IgE levels and FcɛRIβ genetic polymorphism in patients with penicillins allergy , 2004, Allergy.

[32]  A. Roses,et al.  Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. , 2004, Pharmacogenomics.

[33]  S. Knowles,et al.  Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. , 2002, AIDS.

[34]  L. Naldi,et al.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. , 2002, Archives of dermatology.

[35]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[36]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[37]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[38]  L. Vaillant,et al.  Acute generalized exanthematous pustulosis (AGEP) – A clinical reaction pattern , 2001, Journal of cutaneous pathology.

[39]  Theresa Anderson,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis , 1995 .

[40]  R. Stern,et al.  Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.

[41]  S. Mallal,et al.  HLA-B*35 is associated with nevirapine hypersensitivity in the contemporary Western Australian HIV cohort study , 2010 .

[42]  D. Bandyopadhyay,et al.  Indian J Dermatol Venereol Leprol , 2010 .

[43]  L. Naldi,et al.  Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. , 2008, Journal of the American Academy of Dermatology.

[44]  M. Mockenhaupt.  Epidemiology and Causes of Severe Cutaneous Adverse Reactions to Drugs , 2007 .

[45]  B. Thiers.  Medical Genetics: A Marker for Stevens-Johnson SyndromeChung W-H, Hung S-I, Hong H-S, et al (Chang Gung Mem Hosp, Taipei, Taiwan; Inst of Biomedical Sciences, Taipei, Taiwan) Nature 428:486, 2004§ , 2006 .

[46]  R. Stern,et al.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.